NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis $2.08 +0.10 (+4.80%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About CytomX Therapeutics Stock (NASDAQ:CTMX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CytomX Therapeutics alerts:Sign Up Key Stats Today's Range$1.96▼$2.0550-Day Range$1.98▼$3.7252-Week Range$1.90▼$8.21Volume275,421 shsAverage Volume4.74 million shsMarket Capitalization$452.14 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer treatments. Founded in 2008 and headquartered in South San Francisco, California, the company researches therapies designed to target tumors while limiting activity in healthy tissues. Its Probody platform uses molecular masks intended to keep therapeutic antibodies inactive until they encounter enzymes associated with the tumor environment. CytomX applies this approach to investigational medicines, including antibody-drug conjugates and immune-cell-engaging therapies. The company’s pipeline is focused primarily on oncology, and its drug candidates remain in clinical development. CytomX also works with pharmaceutical partners on research and development programs; it does not market approved medicines.AI Generated. May Contain Errors. Read More CytomX Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreCTMX MarketRank™: 2.17377006051 of 5 starsCytomX Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 630th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCytomX Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCytomX Therapeutics has a consensus price target of $12.00, representing about 506.1% upside from its current price of $1.98.Amount of Analyst CoverageCytomX Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CytomX Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is -3.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytomX Therapeutics has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.59% of the float of CytomX Therapeutics has been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 11.99, which indicates bearish sentiment.Change versus previous monthShort interest in CytomX Therapeutics has recently increased by 5.74%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.07 News SentimentCytomX Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for CytomX Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for CTMX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat Follows3 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.80% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CytomX Therapeutics' insider trading history. Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTMX Stock News HeadlinesWedbush Raises Price Target on CytomX Therapeutics to $12 From $11, Keeps Outperform RatingNovember 6, 2026 | marketscreener.comMCytomX Therapeutics, Inc. (CTMX) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | seekingalpha.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 11 at 1:00 AM | Weiss Ratings (Ad)CytomX (CTMX) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | finance.yahoo.comCytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business UpdateNovember 5, 2026 | finance.yahoo.comCytomX Therapeutics: Trading Near Cash Value While Varseta-M Heads Toward Pivotal TrialsNovember 5, 2026 | seekingalpha.comCytomX Therapeutics to Present at Upcoming November Investor ConferencesNovember 2, 2026 | globenewswire.comCytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026October 29, 2026 | globenewswire.comSee More Headlines CTMX Stock Analysis - Frequently Asked Questions How have CTMX shares performed this year? CytomX Therapeutics' stock was trading at $4.26 at the beginning of the year. Since then, CTMX shares have decreased by 53.5% and is now trading at $1.98. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) released its earnings results on Thursday, November, 5th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.02. The biotechnology company earned $1.69 million during the quarter, compared to analyst estimates of $10.38 million. CytomX Therapeutics had a negative net margin of 608.98% and a negative trailing twelve-month return on equity of 33.97%. Read the conference call transcript. When did CytomX Therapeutics IPO? CytomX Therapeutics (CTMX) raised $100 million in an initial public offering (IPO) on Thursday, October 8th 2015. The company issued 6,666,667 shares at a price of $14.00-$16.00 per share. Who are CytomX Therapeutics' major shareholders? Top institutional shareholders of CytomX Therapeutics include Assenagon Asset Management S.A. (0.54%), Peak Financial Advisors LLC (0.21%), Robertson Stephens Wealth Management LLC (0.10%) and IFG Advisory LLC (0.10%). Insiders that own company stock include Sean A Mccarthy, Marcia Belvin, Christopher Ogden, Yu-Waye Chu, Lloyd A Rowland and Jeffrey B Landau. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), SoundHound AI (SOUN), Tesla (TSLA), Advanced Micro Devices (AMD) and Palantir Technologies (PLTR). Company Calendar Last Earnings11/05/2026Today11/11/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CTMX's financial health is in the Red zone, according to TradeSmith. CTMX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CTMX CIK1501989 Webwww.cytomx.com Phone(650) 515-3185Fax650-351-0353Employees69Year Founded2008Price Target and Rating Average Price Target for CytomX Therapeutics$12.00 High Price Target$16.00 Low Price Target$6.00 Potential Upside/Downside+486.8%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.37 million Net Margins-608.98% Pretax Margin-607.31% Return on Equity-33.97% Return on Assets-27.19% Debt Debt-to-Equity RatioN/A Current Ratio7.82 Quick Ratio7.82 Sales & Book Value Annual Sales$14.03 million Price / Sales31.77 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book1.56Miscellaneous Outstanding Shares217,899,000Free Float209,619,000Market Cap$445.60 million OptionableOptionable Beta2.23 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CTMX) was last updated on 11/11/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTMX Stock Alerts